Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
VRDN Stock Chart & Stats
$27.44
-$0.50(-1.51%)
At close: 4:00 PM EST
$27.44
-$0.50(-1.51%)
Day’s Range― - ―
52-Week Range$9.90 - $34.29
Previous CloseN/A
Volume140.31K
Average Volume (3M)814.59K
Market Cap
$2.68B
Enterprise Value$2.08B
Total Cash (Recent Filing)$490.90M
Total Debt (Recent Filing)$23.82M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Mar 05, 2026EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding95,442,010
10 Day Avg. Volume1,087,693
30 Day Avg. Volume814,586
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.94
Price to Sales (P/S)4309.19
P/FCF Ratio-5.59
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue29.41
Enterprise Value/Gross Profit29.41
Enterprise Value/Ebitda-6.96
Forecast
1Y Price Target
$41.86Price Target Upside52.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Administration And Dosing AdvantageElegrobart's subcutaneous monthly dosing and at‑home injection capability reduces treatment burden versus intravenous options, a feature analysts say could support faster commercial adoption.
Financial RunwayAnalyst notes a strong cash position that supports continued development through key trials and reduces execution risk on the path toward potential profitability.
Pivotal Clinical ReadoutsAnalyst cites the upcoming REVEAL-1 pivotal data readout for elegrobart as a primary catalyst that could validate the drug's effectiveness and materially increase company value.
Bears Say
Commercial Adoption DependenceCommercial uptake depends heavily on convincing high-volume oculoplastic surgeons to prescribe new therapies, so limited specialist adoption could constrain market penetration.
Efficacy And Safety Trial RiskAnalyst warns that lower-than-expected efficacy or the emergence of safety issues in pivotal trials would create meaningful downside risk to the stock.
Regulatory UncertaintySignificant regulatory and clinical trial uncertainty remains, and adverse outcomes during review or trials could materially weaken approval prospects and valuation.
Viridian Therapeutics News
VRDN FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was $9.90 and its highest was $34.29 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Viridian Therapeutics’s market cap is $2.68B.
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 11 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$1.019 by $0.679.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate is -0.98.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 95,442,010 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$0.34 in its last earnings report, beating expectations of -$1.019. Following the earnings report the stock price went up 8.293%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Currently, no hedge funds are holding shares in VRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viridian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.86 (52.55% Upside)
$41.86 (52.55% Upside)
Hedge Fund Trend
Increased
By 580.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 8.9%
Last 30 Days ▼ 8.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.56%
12-Months-Change
Fundamentals
Return on Equity
-47.40%
Trailing 12-Months
Asset Growth
-0.57%
Trailing 12-Months
Company Description
Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
VRDN Stock 12 Month Forecast
Average Price Target
$41.86
▲(52.55% Upside)
Technical Analysis
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
4.13% Insiders
25.71% Mutual Funds
14.85% Other Institutional Investors
40.04% Public Companies and Individual Investors